E.F.A (approx. 4.3%) prior to an investment round of about $2 million; the company intends to participate in the fundraising round with an amount of approximately $40,000 Post published:11/12/2025
Investor call on December 14, 2025 at 15:00 regarding the activities of Cleveland and its plans following the receipt of FDA approval Post published:09/12/2025
CD’X received FDA clearance for the IsoPSA test for early detection of prostate cancer Post published:01/12/2025
Engineering collaboration between CardiacSense (4.59%) and a global company in the field of semiconductor technologies Post published:12/10/2025
Participated in an investment round in company X’CD, and holds approximately 4% following the investment Post published:08/10/2025
Expected impairment of holdings in CardiacSense in the H1 2025 reports, in the range of 4–4.5 million NIS Post published:03/08/2025
Investment Agreement in CardiacSense – $250,000 for Approx. 4.17%, Increasing Stake to ~4.34% Post published:29/06/2025
